CD160 and neoplasm: Consequently, CD160-GPI was characterized as an activating receptor as its engagement induces early NK cell cytotoxicity through a PI3-kinase-dependent pathway, potentiates IFN-γ, TNF-α, IL-6 and IL-8 cytokine production and plays a role in the early control of tumor growth [13–16].